SLPI Antibody

• Background :

  SLPI Antibody: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-κ B activation by inhibiting Iκ B degradation in the cytoplasm and competing for NF-κ B binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.

• NCBI Gene ID :

  6590

• Swiss Prot :

  P03973

• Accession Number :

  CAA28187

• Host :

  Rabbit

• Reactivity :

  Human, Mouse

• Clonality :

  Polyclonal

• Conjugation :

  Unconjugated

• Type :

  Primary Antibodies

• Field of Research :

  Innate Immunity

• Purification :

  SLPI Antibody is affinity chromatography purified via peptide column.

• Positive Control :

  Cat. No. 1224 - Daudi Cell Lysate

• Concentration :

  1 mg/mL

• Buffer :

  SLPI Antibody is supplied in PBS containing 0.02% sodium azide.

• Modification :

  None

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  SLPI antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

• Fragment :

  IgG

• Symbol :

  SLPI

• Positive Control 2 :

  Cat. No. 1402 - Mouse Lung Tissue Lysate

• NCBI Official Name :

  Secretory leukocyte peptidase inhibitor

• NCBI Organism :

  Homo sapiens

• Background Reference 01 :

  Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J. Clin. Invest. 1991; 87:2207-15.

• Background Reference 02 :

  Hiemstra PS, Fernie-King BA, McMichael J, et al. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapies. Curr. Pharm. Des. 2004; 10:2891-905.

• Background Reference 03 :

  Jana NK, Gray LR and Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SPLI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J. Virol. 2005; 79:6432-40.

• Background Reference 04 :

  Taggart CC, Cryan S-A, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF-kB binding sites in monocytes and inhibits p65 binding. J. Exp. Med. 2005; 202:1659-68.

• Other Product Names :

  SLPI Antibody: ALP, MPI, ALK1, BLPI, HUSI, WAP4, WFDC4, HUSI-I, Antileukoproteinase, ALP

• Tested Applications :

  ELISA, WB, IHC-P

• Protein ID :

  758101

• Physical Properties :

  Liquid